The estimated Net Worth of Anna Protopapas is at least $2.01 million dollars as of 13 January 2024. Ms. Protopapas owns over 86,958 units of Mersana Therapeutics Inc stock worth over $273,557 and over the last 8 years she sold MRSN stock worth over $0. In addition, she makes $1,739,800 as President, Chief Executive Officer et Director at Mersana Therapeutics Inc.
Sign up
Ms. Protopapas MRSN stock SEC Form 4 insiders trading
Anna has made over 7 trades of the Mersana Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 86,958 units of MRSN stock worth $153,916 on 13 January 2024.
The largest trade she's ever made was exercising 100,000 units of Mersana Therapeutics Inc stock on 15 July 2021 worth over $177,000. On average, Anna trades about 14,909 units every 105 days since 2017. As of 13 January 2024 she still owns at least 154,552 units of Mersana Therapeutics Inc stock.
You can see the complete history of Ms. Protopapas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anna Protopapas biography
Anna Protopapas serves as President, Chief Executive Officer, Director of the Company. Prior to joining Mersana, from October 2010 to October 2014, Ms. Protopapas served as a member of the Executive Committee of Takeda Pharmaceutical Company Limited, a global pharmaceutical company, and held various senior management positions at the company, including serving as President of Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda focused on oncology, where she was responsible for leading the oncology business, and Executive Vice President of Global Business Development, where she was responsible for global acquisitions, partnering, licensing and venture investing. From October 1997 to October 2010, Ms. Protopapas served in various positions at Millennium Pharmaceuticals, including as the Senior Vice President of Strategy and Business Development and a member of the Executive Committee, where she led the company’s business development initiatives. Ms. Protopapas currently serves on the board of directors and the compensation committee for Dicerna Pharmaceuticals, Inc., since her appointment in January 2019. Ms. Protopapas served on the board of directors of Bioverativ from February 2017 until its sale. Previously, she served on the board of directors for Ariad Pharmaceuticals from May 2015 until the sale of the company in January 2017 and served as the Chair of the Compensation Committee beginning in February 2016. She received a bachelor’s degree in science and engineering from Princeton University, a master’s in chemical engineering practice from the Massachusetts Institute of Technology and an M.B.A. from Stanford Graduate School of Business.
What is the salary of Anna Protopapas?
As the President, Chief Executive Officer et Director of Mersana Therapeutics Inc, the total compensation of Anna Protopapas at Mersana Therapeutics Inc is $1,739,800. There are no executives at Mersana Therapeutics Inc getting paid more.
How old is Anna Protopapas?
Anna Protopapas is 55, she's been the President, Chief Executive Officer et Director of Mersana Therapeutics Inc since 2015. There are 11 older and 9 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
What's Anna Protopapas's mailing address?
Anna's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Insiders trading at Mersana Therapeutics Inc
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
What does Mersana Therapeutics Inc do?
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
What does Mersana Therapeutics Inc's logo look like?
Complete history of Ms. Protopapas stock trades at Dicerna Pharmaceuticals Inc et Mersana Therapeutics Inc
Mersana Therapeutics Inc executives and stock owners
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Anna Protopapas,
President, Chief Executive Officer, Director -
Dirk Huebner,
Chief Medical Officer -
Timothy Lowinger,
Chief Science and Technology Officer -
Brian DeSchuytner,
Senior Vice President - Finance and Product Strategy -
Anna Protopapas,
Pres, CEO & Director -
Anna Protopapas M.B.A.,
Pres, CEO & Director -
Dr. Timothy B. Lowinger,
Chief Science & Technology Officer -
Brian C. DeSchuytner,
Sr. VP & CFO -
Dr. Arvin Yang M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Alejandra Veronica Carvajal J.D.,
SVP, Sec. & Chief Legal Officer -
Dr. Tushar Misra Ph.D.,
SVP & Chief Manufacturing Officer -
David Mott,
Independent Chairman of the Board -
Lawrence Alleva,
Independent Director -
Willard Dere,
Independent Director -
Andrew Hack,
Independent Director -
Kristen Hege,
Independent Director -
Martin Huber,
Independent Director -
Eva Jack,
Chief Business Officer -
Chuck Miller,
Senior Vice President - Regulatory Affairs -
Michael Kaufman,
Senior Vice President - Chemistry, Manufacturing and Controls -
Alejandra Veronica Carvajal,
Sr. VP & Chief Legal Officer -
Carla Poulson,
Chief HR Officer -
Radha Iyengar,
VP of Legal Operations -
Sarah Carmody,
Exec. Director of Investor Relations & Corp. Communications -
Ashish Mandelia,
VP, Controller & Principal Accounting Officer -
Mikhail Papisov Ph.D.,
Co-Founder -
Llc Fmr,
-
Peter J Barris,
10% owner -
Forest Baskett,
10% owner -
M James Barrett,
10% owner -
Ravi Viswanathan,
10% owner -
Peter W. Sonsini,
10% owner -
Enterprise Associates 14, L...,
-
Patrick J Kerins,
10% owner -
Scott D Sandell,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Sara M. Nayeem,
Director -
Wayne Foster,
Vice President of Finance -
Donald A Bergstrom,
Chief Medical Officer -
David A Spellman,
Chief Financial Officer -
Enterprise Associates 14, L...,
-
Partners 14, L.P.Nea 14 Gp,...,
-
Enterprise Associates 14, L...,
-
Enterprise Associates 14, L...,
10% owner -
Allene M. Diaz,
Director -
Mohan Bala,
SVP, Chief Development Officer -
Arvin Yang,
SVP, Chief Medical Officer -
Ashish Mandelia,
VP, Chief Accounting Officer -
Tushar Misra,
SVP, Chief Manuf. Officer